The findings highlighted the importance of GLS in breast tumour proliferation and invasiveness and could potentially be used as a target for inhibition via the potent and non-competitive allosteric GLS inhibitor CB−839 (telaglenastat). This evidence concerns the gene GLS and breast neoplasm.